Effects of angiotensin-converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats

被引:12
|
作者
Zhang, RY
Wang, LF [1 ]
Zhang, L
Meng, XN
Li, SJ
Wang, WR
机构
[1] Harbin Med Coll, Clin Hosp 1, Dept Cardiol, Harbin 150001, Peoples R China
[2] Harbin Med Coll, Clin Hosp 1, Dept Pathol, Harbin 150001, Peoples R China
关键词
Smad; ventricular remodeling; angiotensin converting enzyme inhibitor; angiotensin II type I receptor blocker;
D O I
10.1097/00029330-200604020-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Transforming growth factor (TGF) beta(1)-Smads signal plays an important role in cardiac remodeling following myocardial infarction (MI). In addition, both angiotensin converting enzyme inhibitor (ACEI) and angiotensin II type I receptor blocker (ARB) can effectively prevent left ventricular remodeling. The current study focused on whether the combination of ACEI and ARB is more beneficial for preventing ventricular remodeling and whether Smad proteins mediate this beneficial effect. Methods MI was induced by ligating the left anterior descending coronary artery in rats. Twenty-four hours after ligation, the survived rats were randomly divided into five groups and treated for 8 weeks: placebo group, ACEI group (benazepril 10 mg (.) kg(-1) (.) d(-1)), ARB group (irbesartan 50 mg (.) kg-(1 .) d(-1)), ACEI + ARB group (benazepril 10 mg (.) kg (.) d(-1) + irbesartan 50 mg (.) kg (.) d(-1)) and control group (sham-operated rats). After 8 weeks, we examined the following indexes: the ratio of ventricular weight to body weight,(VW/BW), left ventricular end diastolic dimension (LVDd), ejection fraction (EF), fractional shortening (FS), ratio of E-wave to A-wave velocity, collagen of noninfarcted zone, the mRNA expression of TGF beta(1), Smad 2, and Smad 3 by RT-PCR in noninfarcted zone, the protein expression of Smad 2 and Smad 3 in noninfarcted zone by Western blot. Results VW/BW significantly increased in the placebo groups compared with that in the control group (P < 0.01). This increase was limited in ACEI, ARB, and combined groups (P < 0.01 compared with placebo group). There was no significant difference among the three actively treated groups. Collagen was increased in placebo group (5.68 +/- 0.5)% compared with that in control group (P < 0.01). ACEI, ARB and combined treatment attenuated this increase of collagen [(4.3 +/- 0.5)%, (3.5 +/- 0.5)%, (3.2 +/- 0.4)%] in comparison with that in placebo group (P < 0.01 respectively). Combined treatment showed more significant effect on collagen deposition. EF and FS significantly decreased, LVDd and E/A significantly increased in placebo group compared with that in control group (P < 0.01 respectively). ACEI, ARB and combined treatment ameliorated these indexes (P < 0.01 compared with placebo group). The mRNA expression of TGF beta(1), Smad 2, and Smad 3 (0.700 +/- 0.045, 0.959 +/- 0.037 and 0.850 +/- 0.051) increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective in decreasing TGF beta(1) and Smad mRNA expression than ACEI treatment (P < 0.01). The expression of Smad 2 and Smad 3 protein increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective than ACEI alone (P < 0.01). Conclusions TGF beta(1)-Smads signal activation is correlated with ventricular remodeling following MI. ACEI and ARB treatment prevents ventricular remodeling by inhibiting expression of Smad 2 and Smad 3.. ARB and combined treatment are more effective than ACEI alone.
引用
收藏
页码:649 / 655
页数:7
相关论文
共 50 条
  • [41] Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis
    Ujiie, Y
    Hirosaka, A
    Mitsugi, M
    Ohwada, T
    Igarashi, M
    Kijima, M
    Komatsu, N
    Hisa, S
    Abe, Y
    Tsuda, T
    Yaoita, H
    Maehara, K
    Maruyama, Y
    INTERNATIONAL HEART JOURNAL, 2006, 47 (02) : 173 - 184
  • [42] Angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use and outcomes in patients with colorectal cancer
    Tuazon, Sherilyn Alvaran
    King, Gantry Teng
    Cruz, Joanna Sta.
    Chae, Young K.
    Koc, Jean B. Ong Klan
    Hegarty, Sarah
    Leighton, John Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria
    Chu, Chi D.
    Powe, Neil R.
    Estrella, Michelle M.
    Shlipak, Michael G.
    McCoy, Ian E.
    Tuot, Delphine S.
    MAYO CLINIC PROCEEDINGS, 2022, 97 (11) : 2099 - 2106
  • [44] COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy
    Kussmaul, William G., III
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (03) : 237 - 238
  • [45] The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats
    Higashiura, KS
    Ura, N
    Takada, T
    Li, Y
    Torii, T
    Togashi, N
    Takada, M
    Takizawa, H
    Shimamoto, K
    AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (03) : 290 - 297
  • [46] Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination
    Tsikouris, James P.
    Cox, Craig D.
    Simoni, Jan S.
    Seifert, Charles F.
    Peek, Miranda C.
    Meyerrose, Gary E.
    CORONARY ARTERY DISEASE, 2006, 17 (05) : 439 - 445
  • [47] Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy
    Watanabe, K
    Juan, W
    Narasimman, G
    Ma, ML
    Inoue, M
    Saito, Y
    Wahed, MI
    Nakazawa, M
    Hasegawa, G
    Naito, M
    Tachikawa, H
    Tanabe, N
    Kodama, M
    Aizawa, Y
    Yamamoto, T
    Yamaguchi, K
    Takahashi, T
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 41 : S93 - S97
  • [48] A comparison of angiotensin-converting enzyme inhibitor and Angiotensin II type 1 receptor blocker on carotid artery intima and media thickness in hypertensives
    Uchiyama-Tanaka, Y
    Matsubara, H
    Mori, Y
    Murasawa, S
    Shibasaki, Y
    Iwasaka, T
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 241A - 241A
  • [49] Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker
    Ishibashi, Ken
    Kurisu, Satoshi
    Kato, Yasuko
    Mitsuba, Naoya
    Dohi, Yoshihiro
    Nishioka, Kenji
    Kihara, Yasuki
    HEART AND VESSELS, 2013, 28 (01) : 7 - 11
  • [50] Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker
    Ken Ishibashi
    Satoshi Kurisu
    Yasuko Kato
    Naoya Mitsuba
    Yoshihiro Dohi
    Kenji Nishioka
    Yasuki Kihara
    Heart and Vessels, 2013, 28 : 7 - 11